State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia

被引:22
|
作者
Sonnenschein, Susan F. [1 ,2 ,3 ]
Gill, Kathryn M. [1 ,2 ,3 ]
Grace, Anthony A. [1 ,2 ,3 ]
机构
[1] Univ Pittsburgh, Ctr Neurosci, Dept Neurosci, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Ctr Neurosci, Dept Psychiat, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Ctr Neurosci, Dept Psychol, Pittsburgh, PA 15260 USA
关键词
ANTIPSYCHOTIC-DRUG; DEPOLARIZATION BLOCK; IN-VIVO; METHYLAZOXYMETHANOL ACETATE; SUPERSENSITIVITY PSYCHOSIS; ATYPICAL NEUROLEPTICS; CLINICAL-RESPONSE; ANIMAL-MODEL; HALOPERIDOL; RECEPTORS;
D O I
10.1038/s41386-018-0219-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aripiprazole is an antipsychotic drug characterized by partial agonist activity at D-2 receptors to normalize both hyperdopaminergic and hypodopaminergic states. Traditional D-2 antagonist antipsychotic drugs have been shown previously to reduce dopamine neuron activity through action on D-2 autoreceptors to produce an overexcitation-induced cessation of cell firing, referred to as depolarization block. It is unclear whether aripiprazole reduces dopamine neuron activity via inhibition or, as seen following D-2 antagonist administration, depolarization block. The impact of acute and repeated aripiprazole treatment was examined in the methylazoxymethanol acetate (MAM) rodent model to observe its effects on a hyperdopaminergic system, compared to normal rats. We found that administration of aripiprazole acutely or after 1 or 7 days of withdrawal from 21-day repeated treatment led to a decrease in the number of spontaneously active dopamine neurons in MAM rats but not in controls. This reduction was not reversed by apomorphine (100-200 mu g/kg i.p. or 20 mu g/kg i.v.) administration, suggesting that it was not due to depolarization block. In contrast, 1 h after induction of depolarization block of dopamine neurons by acute haloperidol treatment (0.6 mg/kg i.p.), aripiprazole (1 mg/kg, i.p.) reversed the depolarization block state. Therefore, aripiprazole rapidly reduced the hyperdopaminergic activity selectively in MAM rats. The reduction is unlikely due to depolarization block and persists following 7-day withdrawal from repeated treatment. Aripiprazole also removes haloperidol-induced depolarization block in MAM rats, which may underlie the acute psychotic state often observed with switching to this treatment.
引用
收藏
页码:572 / 580
页数:9
相关论文
共 50 条
  • [41] Occupancy of dopamine D2 receptors by aripiprazole at steady state dosing in schizophrenia measured with [18F] fallypride PET
    Frankle, WG
    Narendran, R
    Gil, R
    Hwang, DR
    Hwang, YY
    Scher, E
    Cangiano, C
    Laruelle, M
    Abi-Dargham, A
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S116 - S116
  • [42] Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
    Kikuchi, Tetsuro
    Maeda, Kenji
    Suzuki, Mikio
    Hirose, Tsuyoshi
    Futamura, Takashi
    McQuade, Robert D.
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2021, 41 (02) : 134 - 143
  • [43] Occupancy of dopamine D2 receptors by aripiprazole at steady state dosing in schizophrenia measured with [18F]fallypride PET
    Frankle, WG
    Narendran, R
    Gil, R
    Hwang, DR
    Hwang, YY
    Scher, E
    Cangiano, C
    Laruelle, M
    Abi-Dargham, A
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 219S - 219S
  • [44] Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
    Keks, Nicholas
    Hope, Judith
    Schwartz, Darren
    McLennan, Harold
    Copolov, David
    Meadows, Graham
    CNS DRUGS, 2020, 34 (05) : 473 - 507
  • [45] Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
    Nicholas Keks
    Judith Hope
    Darren Schwartz
    Harold McLennan
    David Copolov
    Graham Meadows
    CNS Drugs, 2020, 34 : 473 - 507
  • [46] ANTAGONISM OF LIMBIC AND EXTRAPYRAMIDAL ACTIONS OF INTRACEREBRALLY INJECTED DOPAMINE BY ERGOLINES WITH PARTIAL D2 AGONIST ACTIVITY IN THE RAT
    CAMPBELL, A
    BALDESSARINI, RJ
    YEGHIAYAN, S
    BRAIN RESEARCH, 1992, 592 (1-2) : 348 - 352
  • [47] Dopamine D2 receptor partial agonists in the treatment of schizophrenia - example of brexpiprazole
    Blizniewska-Kowalska, Katarzyna
    Galecki, Piotr
    PSYCHIATRIA POLSKA, 2024, 58 (04) : 581 - 593
  • [48] Preclinical Pharmacology of OPC-34712: A Novel Compound with Dopamine D2 Receptor Partial Agonist Activity
    Kikuchi, Tetsuro
    Maeda, Kenji
    Sugino, Haruhiko
    Akazawa, Hitomi
    Amada, Naoki
    Jordan, Shaun
    Shimada, Jun
    Yamashita, Hiroshi
    Ito, Nobuaki
    Forbes, Robert A.
    McQuade, Robert D.
    BIOLOGICAL PSYCHIATRY, 2011, 69 (09) : 95S - 95S
  • [49] Aplindore (DAB-452) exhibits high affinity dopamine D2 receptor partial agonist activity
    Pausch, M
    Heinrich, JN
    Lai, M
    Carroll, K
    Homby, G
    Popiolek, M
    Jiang, L
    Stack, G
    Marquis, KL
    Andree, TH
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 308 - 308
  • [50] Partial agonist activity of aripiprazole at D2 and 5-HT1A receptors: Evidence from in vitro binding studies
    Jordan, S
    Tadori, Y
    McQuade, R
    Yocca, F
    Kikuchi, T
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 155 - 155